144 ·Filed Jun 11, 2026

TNGX

Tango Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001950047-26-005968
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine Form 144 filing for a tax-covering sale on vested restricted stock by an officer. The $133K amount is immaterial — no trading signal is generated by this notice of intent to sell.

DirectionNeutral
Confidencehigh
Horizonimmediate
Latest settled — T+20d ⚠ clustered
TNGX ▲ +0.39% at T+20d
NEUTRAL call ✓ call won +0.39% · α vs SPY -1.39% · entry $30.94 → $31.06
Next anchor: T+60d due 24d ago
Latest observation: T+58 -48.20% FF3 residual α
Entry anchored
Jun 11, 03:59 PM ET
via exchange tick
T+1d
+6.33%
call +6.33% · α +4.57%
$32.90
settled 4mo ago
T+5d
-9.60%
call -9.60% · α -10.27%
$27.97
settled 4mo ago
T+20d
+0.39%
call +0.39% · α -1.39%
$31.06
settled 3mo ago
T+60d
—
call — · α —
—
due 24d ago

Price Chart

Loading chart...

Executive Summary

Officer Daniella Beckman filed a Form 144 notice of intent to sell 4,446 shares of TNGX common stock, with an estimated value of approximately $133,380. The shares were acquired upon vesting of restricted stock between April 2017 and May 2026. This is a routine, tax-related sale that is negligible relative to Beckman's 1.79M share holdings and the company's $4.1B market cap.

Key Facts

  • Officer Daniella Beckman intends to sell 4,446 shares of TNGX common stock
  • Estimated sale value of approximately $133,380 (roughly $30/share)
  • Shares acquired upon vesting of restricted stock from April 2017 through May 2026
  • Sale represents approximately 0.25% of Beckman's disclosed 1,791,726 share holdings
  • Broker for the proposed sale is Morgan Stanley Smith Barney LLC

Financial Impact

~$133,380 sale value, representing less than 0.01% of TNGX's $4.1B market cap and a trivial reduction in insider holdings

insider holdings

Risk Factors

  • No material risks identified from this routine insider sale filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (18 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005968
Document: 0001950047-26-005968-index.html0001950047-26-005968
Document: 0001950047-26-005968.txt0001950047-26-005968
19 reports for TNGX
Performance horizon
63% Hit rate 5 of 8 directional calls best @ T+60▲ +29.28%Jun 8, 2026
Filters
Rows
Reports for TNGX — sortable, filterable
TypeNow
Aug 11, 2026
7w ago
8-K
BEARISH ★ 6/10
$25.58 $25.20▲ +1.49%▲ +1.04%$23.20 (+9.28%)
Aug 11, 2026
7w ago
8-K
BULLISH ★ 7/10
$26.34 $25.44▼ −3.42%▼ −3.01%$23.20 (−11.90%)
Aug 11, 2026
7w ago
Press Release
BULLISH ★ 7/10
$26.34 $25.44▼ −3.42%▼ −3.01%$23.20 (−11.90%)
Aug 9, 2026
7w ago
Institutional Cluster
BULLISH ★ 6/10
$27.67 $25.29▼ −8.60%▼ −8.55%$23.20 (−16.14%)
Aug 6, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$27.07 $25.60▼ −5.43%▼ −5.83%$23.20 (−14.28%)
Jun 11, 2026
16w ago
144
NEUTRAL ★ 2/10
$30.94 $27.97▼ −9.60%▼ −10.27%$23.20 (−25.00%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 5/10
$29.82 $32.29▲ +8.28%▲ +7.85%$23.20 (−22.18%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 4/10
$29.82 $32.29▲ +8.28%▲ +7.85%$23.20 (−22.18%)
Jun 10, 2026
16w ago
424B5
MIXED ★ 6/10
$29.82 $32.29▲ +8.28%▲ +7.85%$23.20 (−22.18%)
Jun 10, 2026
16w ago
144
NEUTRAL ★ 2/10
$29.82 $32.29▲ +8.28%▲ +7.85%$23.20 (−22.18%)
Showing 10 of 19

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access